Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Pharmacol.

Sec. Respiratory Pharmacology

Volume 16 - 2025 | doi: 10.3389/fphar.2025.1651122

This article is part of the Research TopicExploring Novel In Vitro Models for Cystic Fibrosis ResearchView all 3 articles

Nasal cells as a bronchial cell surrogate for pre-clinical assessment of drug response in cystic fibrosis

Provisionally accepted
Malina  BarillaroMalina Barillaro1,2Julie  AvolioJulie Avolio2Sharaniyaa  BalachandranSharaniyaa Balachandran3Claire  BartlettClaire Bartlett2Wan  IpWan Ip2Hong  OuyangHong Ouyang2Wenming  DuanWenming Duan2Joseph  ZabnerJoseph Zabner4Shaf  KeshavjeeShaf Keshavjee3Christine  E. BearChristine E. Bear5Theo  MoraesTheo Moraes2Tanja  GonskaTanja Gonska2*
  • 1Department of Physiology, University of Toronto, Toronto, Canada
  • 2Program in Translational Medicine, The Hospital for Sick Children, Toronto, Canada
  • 3Toronto Lung Transplant Program, Division of Thoracic Surgery, Toronto General Hospital, Toronto, Canada
  • 44Department of Internal Medicine, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, United States
  • 5Molecular Medicine, The Hospital for Sick Children, Toronto, Canada

The final, formatted version of the article will be published soon.

Patient-derived airway cell cultures are used in personalized medicine strategies for people with cystic fibrosis (pwCF) to predict potential clinical response to cystic fibrosis transmembrane conductance regulator (CFTR) modulator drugs. While bronchial epithelial cells from lung explants (HBEx) are the gold standard for CFTR functional measurements, nasal epithelial cells (HNE) are a more practical tissue source resulting in widespread use for preclinical functional platforms. HNE have so far not been rigorously validated against the gold standard for this purpose. In this study, we collected nasal and bronchial cells, and lung explants from pwCF undergoing lung transplantation as well as non-CF controls. Comparative studies in non-CF cells showed that while CFTR-mediated transepithelial currents in HNE underestimated those in HBEx, the magnitude of the CFTR modulator response was similar between CF HNE, brushed HBE (HBEb), and HBEx with significant correlation between matched HNE and HBEb from 16 pwCF. These findings confirm use of HNE as surrogate of bronchial airway for preclinical drug testing with report of drug responses in relation to the tissue-specific non-CF or baseline controls rather than as absolute results. Furthermore, CF centres offering HNE-based drug testing utilize different techniques, challenging the comparison of results between centres. We show how culture media, use of fresh or freeze-thawed cells as well as difference in Ussing technique impact the magnitude of measured CFTR function, which is why we suggest diligence in reporting of these factors when presenting CFTR modulator drug response results.

Keywords: Nasal cells, Cystic Fibrosis, CFTR modulator, electrophyiology, in vitro model

Received: 20 Jun 2025; Accepted: 14 Aug 2025.

Copyright: © 2025 Barillaro, Avolio, Balachandran, Bartlett, Ip, Ouyang, Duan, Zabner, Keshavjee, Bear, Moraes and Gonska. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Tanja Gonska, Program in Translational Medicine, The Hospital for Sick Children, Toronto, Canada

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.